Form 4: Karyopharm CFO Awarded 43,650 Restricted Stock Units
Insider Transaction Report
Karyopharm Therapeutics Inc.'s EVP, CFO & Treasurer, Lori Macomber, received an award of 43,650 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan.
Summary
- Lori Macomber, EVP, CFO & Treasurer of Karyopharm Therapeutics Inc. (KPTI), was awarded 43,650 restricted stock units (RSUs).
- The RSUs were granted on October 15, 2025, at a price of $0 per unit.
- These RSUs will convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
- The entire award vests 100% on December 31, 2026.
- Following this transaction, Lori Macomber beneficially owns 54,316 shares of common stock.
- All reported amounts reflect a one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
Sentiment
Score: 7
Explanation: The award of restricted stock units to a key executive is generally viewed positively as it aligns management's interests with long-term shareholder value. It's a routine compensation event, not indicative of extraordinary performance or issues.
Positives
- The award of 43,650 restricted stock units to a key executive, Lori Macomber, aligns management interests with shareholder value.
- The award is part of the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, indicating a structured and approved compensation approach.
Future Outlook
The awarded restricted stock units are scheduled to vest 100% on December 31, 2026, indicating a future milestone for executive compensation.
Industry Context
Executive compensation through equity awards like RSUs is a standard practice in the biotechnology and pharmaceutical industry, aiming to incentivize long-term performance and align executive interests with shareholder returns.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan | Award of restricted stock units made pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. | 2025-10-15 | Reinforces the company's established equity compensation framework for executives, aligning their incentives with long-term company performance. |
Stakeholder Impact
- Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance and shareholder value.
Next Steps
- Vesting of 43,650 restricted stock units on December 31, 2026.
Key Dates
| Date | Description |
|---|---|
| 2025-02-25 | Effective date of one-for-fifteen reverse stock split. |
| 2025-10-15 | Date of award of restricted stock units (RSUs) to Lori Macomber. |
| 2025-10-16 | Date Form 4 was signed by Attorney-in-Fact for Lori Macomber. |
| 2026-12-31 | Vesting date for 100% of the awarded restricted stock units. |
Keywords
Karyopharm Therapeutics, KPTI, Lori Macomber, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.